TY - JOUR
T1 - Effectiveness of inactivated quadrivalent influenza vaccine in the 2015/2016 season as assessed in both a test-negative case-control study design and a traditional case-control study design
AU - Kimiya, Takahisa
AU - Shinjoh, Masayoshi
AU - Anzo, Makoto
AU - Takahashi, Hiroki
AU - Sekiguchi, Shinichiro
AU - Sugaya, Norio
AU - Takahashi, Takao
PY - 2018/4/21
Y1 - 2018/4/21
N2 - Both traditional case-control studies (TCCSs) and test-negative case-control studies (TNCCSs) are commonly used to assess influenza vaccine effectiveness (VE). To compensate for the fact that observational studies are susceptible to bias, we combined both methods to assess VE in one geographical area during the 2015/2016 season, when influenza A (H1N1)pdm was dominant. Our TNCCS covered 331 children aged 6 months to 15 years who visited our hospital with fever, including 182 with influenza, and our TCCS covered 812 pediatric outpatients aged 6 months to 15 years, including 214 with influenza. Influenza infection and vaccination history were reviewed, and VE was calculated as (1 − odds ratio) × 100. In the TNCCS, VE against influenza A was 68% (95% CI 47–81) overall, and 70% (48–83) for those given two doses; against influenza B, VE was 37% (− 12–64) overall and 49% (2–74) for two doses. In the TCCS, VE against influenza A was 44% (15–63) overall and 44% (13–64) for two doses, and VE against influenza B was 24% (− 19–52) overall and 41% (3–64) for two doses. Conclusion: Both studies confirmed significant VE against influenza A, significant two-dose VE against influenza B, and better two-dose VE than one-dose VE.(Table presented.)
AB - Both traditional case-control studies (TCCSs) and test-negative case-control studies (TNCCSs) are commonly used to assess influenza vaccine effectiveness (VE). To compensate for the fact that observational studies are susceptible to bias, we combined both methods to assess VE in one geographical area during the 2015/2016 season, when influenza A (H1N1)pdm was dominant. Our TNCCS covered 331 children aged 6 months to 15 years who visited our hospital with fever, including 182 with influenza, and our TCCS covered 812 pediatric outpatients aged 6 months to 15 years, including 214 with influenza. Influenza infection and vaccination history were reviewed, and VE was calculated as (1 − odds ratio) × 100. In the TNCCS, VE against influenza A was 68% (95% CI 47–81) overall, and 70% (48–83) for those given two doses; against influenza B, VE was 37% (− 12–64) overall and 49% (2–74) for two doses. In the TCCS, VE against influenza A was 44% (15–63) overall and 44% (13–64) for two doses, and VE against influenza B was 24% (− 19–52) overall and 41% (3–64) for two doses. Conclusion: Both studies confirmed significant VE against influenza A, significant two-dose VE against influenza B, and better two-dose VE than one-dose VE.(Table presented.)
KW - 2015/2016 season
KW - Inactivated quadrivalent influenza vaccine
KW - Influenza vaccine effectiveness
KW - Test-negative case-control study
KW - Traditional case-control study
UR - http://www.scopus.com/inward/record.url?scp=85045748385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045748385&partnerID=8YFLogxK
U2 - 10.1007/s00431-018-3145-7
DO - 10.1007/s00431-018-3145-7
M3 - Article
C2 - 29680993
AN - SCOPUS:85045748385
SP - 1
EP - 9
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
ER -